Lexicon Pharmaceuticals (LXRX) Share-based Compensation (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Share-based Compensation data on file, last reported at $3.1 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 1.15% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 27.78% decrease from a year earlier, with the FY2025 full-year figure at $3.2 million, down 75.98% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.1 million, up from $43000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for LXRX reached as high as $4.3 million in Q1 2024 and fell as low as -$10.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $2.6 million in 2023.
• Across the five-year window, Share-based Compensation soared 139.14% in 2022 and sank 415.3% in 2023, its largest moves.
• Year by year, Share-based Compensation stood at $3.3 million in 2022, then sank by 415.3% to -$10.3 million in 2023, then surged by 114.92% to $1.5 million in 2024, then sank by 97.2% to $43000.0 in 2025, then soared by 7058.14% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $3.1 million in Q1 2026, $43000.0 in Q4 2025, and $1.8 million in Q3 2025.